the aid library

LIST OPTIONS

Filter

5993

Download (207)

View PDF (376)

System change for better public health in North Macedonia: a roadmap: report of the public health retreat, Ohrid, 1–3 October 2019

World Health Organization WHO (2021) C_WHO

Download (286)

View PDF (329)

The United Nations Convention on the rights of the child and implications for clinical, practice, policy and research

M. L. Belfer; S. Song IACAPAP (2012) C2

Miscellaneous Chapter J.7

Download (222)

View PDF (341)

A step-by-step Guide to develop National Action Plans for Noma Prevention and Control in Priority Countries

World Health Organisation (WHO) (2020) C_WHO

Noma (cancrum oris) is a severe gangrenous disease of the mouth and face. It mostly affects children between the ages of 2 and 6 years living in extreme poverty. In addition to the known factors such as malnutrition, lack of vaccination in children and poor oral hygiene, several social and environme... more

Download (271)

View PDF (486)

Nutritional interventions update: multiple micronutrient supplements during pregnancy

World Health Organization WHO (2020) C_WHO

The World Health Organization’s comprehensive antenatal care (ANC) guideline WHO recommendations on antenatal care for a positive pregnancy experience was published in 2016 with the objective of improving the quality of routine health care that all women and adolescent girls receive during pregnan... more

Download (266)

View PDF (558)

Zoonoses: Blurred Lines of Emergent Disease and Ecosystem Health - UNEP Frontiers 2016 Report: Emerging Issues of Environmental Concern

United Nations Environment Programme (2016) C2

The 20th century was a period of unprecedented ecological change, with dramatic reductions in natural ecosystems and biodiversity and equally dramatic increases in people and domestic animals. Never before have so many animals been kept by so many people—and never before have so many opportunities... more

Download (233)

View PDF (563)

Response to the Ukraine Crisis: interim report, February to June 2022

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

Saving lives is the priority of WHO’s response in Ukraine. WHO works to ensure time-critical, lifesaving multisectoral assistance, non-discriminatory access to emergency and essential health services and priority prevention programmes, and laying the foundation for longer-term health systems recov... more

Download (290)

View PDF (410)

Sprachmittlung für geflüchtete Menschen im Bereich der sexuellen und reproduktiven Gesundheit und Rechte. Praxisempfehlungen für Sprachmittler*innen

Yakmanesh, N. et al. Der Paritätische Gesamtverband e.V. (2023) CC

Es fasst in kompakter und praxistauglicher Art und Weise die Erfahrungen und Impulse aus dem ersten Projektjahr zusammen. Sie gibt wertvolle Handlungsempfehlungen für die Praxis der Sprachmittlung im Bereich der sexuellen und reproduktiven Gesundheit und Rechte. Sie richtet sich als Leitfaden direk... more

Download (1684)

View PDF (2825)

Neonatal Tetanus Elimination Field Guide

Pan American Health Organisation PAHO (2005) C_WHO

In many countries neonatal tetanus is responsible for half of all neonatal deaths due to vaccine-preventable diseases and for almost 14% of al¡ infant deaths. It is estimated that in the 1970s more than 10,000 newborns died annually from neonatal tetanus in the Americas. Neonatal tetanus is prevent... more

Download (400)

View PDF (414)

Harmonized health facililty assessment (HHFA)

World Health Organization WHO (2021) C_WHO

Combined questionnaire Core

Download (748)

View PDF (346)

Apart Together survey

World Health Organization WHO (2021) C_WHO

Preliminary overview of refugees and migrants self-reported impact of COVID-19 The study surveyed over 30,000 refugees and migrants living in 170 countries. Many of the respondents had fled war or dire economic conditions in their home country only to be faced with the additional challenges posed b... more

Download (1419)

View PDF (1567)

Kenya National Pharmaceutcal Policy: 2008

Dr F Siyoi, Dr C Forshaw, Dr J Mbuva ,Dr M Thuo, Dr N Mucheru, Dr E Ominde-Ogaja, Dr R Mbindyo, Mrs R Kirika Minister for Medical Services (2008) C1

Download (427)

View PDF (919)

Diagnostic target product profiles for monitoring, evaluation and surveillance of schistosomiasis control programmes

World Health Organization WHO (2021) C_WHO

Health ministries currently lack effective tools for monitoring and evaluation of schistosomiasis control programmes. Egg detection can be used, but the cost, challenges of obtaining samples, and the need for trained personnel and equipment limit the frequency of monitoring. The purpose of this TPP ... more

Download (835)

View PDF (1309)

Nepal Global Health Initiative Strategy

Nepal GHI Strategy (2010) C1

Download (417)

View PDF (612)

Living Conditions among People with Activity Limitations in Zambia: A National Representative Study.

Arne H Eide & ME Loeb SINTEF Health Research (2006) C1

This research report provides results from the study on living conditions among people with disabilities in Zambia. Comparisons are made between individuals with and without disabilities and also between households with and without a disabled family member. Results obtained in Zambia are also compar... more

Download (329)

View PDF (429)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

External Link

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Download (422)

View PDF (644)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (572)

View PDF (764)

Interim National Guidelines for Monkeypox Outbreak Response

Federal Ministry of Health - Nigeria Centre for Disease Contro (2017) C2

This document provides information and recommendations for action, based on the current available knowledge around monkeypox. It is a first draft which will be updated in light of evolving evidence and additional information as they become available.

Download (18353)

View PDF (2959)

Paediatrics for Doctors in Papua New Guinea

Frank Shann and John Vince (2003)

A guide for doctors providing health services for children. 2nd edition

Download (1343)

View PDF (2319)

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended

Prof. G. N. Lule, Dr. B. Nyawira Gastroenterology Society of Kenya , Republic of Keny (2015) C1

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya recommended

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended